Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Disorders of Ca/phosphate homeostatsis: Hyper- and hypocalcemias and the osteoporosis Kádár Kristóf Deparment of Oralbiology 2016 Calcium and Phosphate – Why is it important? • Phosphate is component of DNA, RNA, ATP, phospholipids, and pH buffers – ~750 g in adult skeleton – plasma concentration is 0.81-1.45 mmol/L – 2 plasma forms: HPO42- and H2PO4- • Calcium needed in neurons, muscle contraction,blood clotting and exocytosis – – – – – ~1100 g (28.6 mol) in adult skeleton plasma concentration is ~ 2.5 mmol/L In blood, 50% of Ca2+ binds to albumin Plasma ionized (free) Ca2+ level: 1.1-1.4 mmol/L. ionized (free) Ca2+biological effect (regulation signal) Calcium and Phosphate – Why is it important FOR A DENTIST? • Complex and robust regulation exist to maintain ion levels in the physiological range • Main components of the mineralized tissue • Chronic imbalances of phosphate/calcium regulation results in the altered composition and mechanical properites of the hard tissues! Ion Imbalances • Changes in phosphate levels little effect – chronic changes in phosphate levels→ changes in serum calcitriol, PTH, FGF23, – Ca2+ • Changes in calcium can be serious even life threatening – hypocalcemia is deficiency of blood calcium (causes excitability of nervous system if too low) • Patomechanism: with less calcium, sodium channels open more easily, sodium enters cell and excites neuron • muscle spasms, tremors or tetany ~ 1.5 mmol/L • laryngospasm and suffocation ~ 1.0 mmol/L – hypercalcemia is excess of blood calcium • Patomechanism: binding to cell surface makes sodium channels less likely to open, depressing nervous system • muscle weakness and sluggish reflexes, cardiac arrest ~ 3.0 mmol/L • • Calcium/phosphate homeostasis depends on calcitriol,calcitonin, PTH and FGF23 regulation Hormonal control of calcium balance 7-Dehydrocholesterol + UV light (skin) vitamin D3 kidney PTH + liver + - 25(OH)D3 Prostate, breast, colon, ß-cells etc. + FGF23 + 1,25(OH)D3 autocrine effects: 1,25(OH)D3 endocrine effects: + 1,24,25(OH)D3 inactive! Calcitriol (activated vitamin D) • Acts through the regulation of gene expression – VDR receptor • Calcitriol behaves as a hormone that raises blood calcium concentration – Increases intestinal absorption (calbindin, TRPV6) and absorption from the skeleton – increases stem cell differentiation into osteoclasts – promotes urinary reabsorption of calcium ions • Abnormal softness (rickets) in children and (osteomalacia) in adults without vitamin D Parathyroid Hormone • Glands on posterior surface of thyroid • Se [Ca2+]↓ CaSR PTH↑ • Main endocrine eunction raise calcium blood level (Classical targets: osteblast, osteoclast, chondrocyte, renal tubular cells) – causes osteoblasts to release osteoclaststimulating factor (RANKL) increasing osteoclast population – promotes calcium resorption by the kidneys – promotes calcitriol synthesis in the kidneys (activates 1(OH)-ase) – inhibits phospahte reabsorption in the kidneys (inhibits SLC34A1, SLC34A3) – inhibits collagen synthesis and bone deposition by osteoblasts • Non-classical target cells: – smooth muscle (relaxation → hypotensive effect) – cardiomyocytes (hypertrophy – eg. LVH in dialysed patients) – sinus node (positive chronotropic effect) FGF-23 • Fibroblast growth factor-23 • Produced mainly by bone and connective tissue • Effects – In the kidney • inhibits tubular P reuptake – phosphaturia • inhibits 1α-hydroxilase activity – Induces 24-hydroxilase activity (calcitriol ↓) – indirectly decreases P absorption • Other effects – Parathyroids: • directly inhibits PTH secretion – Cardiac: • directly induces cardiac hypertrophy • FGF23 mRNA expression is stimulated by: – calcitriol – hyperphosphataemia (indirect effect) The regulation of calcium and phosphate homeostasis by PTH, vitamin D and FGF23 DiGirolamo, D. J. et al. (2012) The skeleton as an endocrine organ Nat. Rev. Rheumatol. doi:10.1028/nrrheum.2012.157 Calcitonin • Secreted (C cells of thyroid gland) when calcium concentration rises too high • Functions – reduces osteoclast activity as much as 70% – increases the number and activity of osteoblasts • Important in children, little effect in adults – osteoclasts more active in children – deficiency does not cause disease in adults • Reduces bone loss in osteoporosis Other hormones and local factors • Hormones – – – – – • Factors presumedly produced by the osteoblasts: – – – – • insulin growth hormone (GH) glucocorticoids testosterone, oestrogen thyroid hormones IGF I FGF PDGF TGFb Factors produced by chondrocytes – IGF I – bFGF – TGFb • Factors produced by blood cells – IL-1, IL-6 – Colony stimulating factors – TNF Main controlling mechanisms of calcium homeostasis Calcium balance Causes of hypocalcemia Hypoparathyroidism Etiology • Surgical Hypoparathyroidism • Idiopathic Hypoparathyroidism multi endocrine deficiencyautoimmunecandidiasis (MEDAC) • Functional Hypoparathyroidism (low magnesium intake, malabsorption) Clinical features of hypoparathyroidism • Neuromusclar manifestation – – – – Paresthesias (numbness, tingling) Hyperventilation Adrenergic symptoms (increased epinephrine) Signs of latent tetany • Chvostek`s sign • Trousseau`s sign • Other clinical manifestation – – – – Posterior lenticular cataract Cardiac manifestation Dental manifestation Malabsorption syndrome Clinical symptomes of hypocalcemic states Etiologies of hypercalcemia Increased GI Absorption • • Milk-alkali syndrome Elevated calcitriol – Vitamin D excess: Excessive dietary intake, granulomatous disease – Elevated PTH – Hypophosphatemia Increased loss from bone • Increased net bone resorption – Elevated PTH: Hyperparathyroidism (ie. primary hyperparathyroidism) • Malignancy – Osteolytic metastases, PTHrP secreting tumor, multiple myeloma Increased bone turnover – Paget’s disease, hyperthyroidism Decreased bone mineralization • • Elevated PTH, aluminum toxicity Decreased urinary excretion • Thiazide diuretics, elevated calcitriol, elevated PTH Consequences of hypercalcemia • Gastrointestinal – obstipatio, nausea, vomitting; ileus, abdominal pain – ulcus pepticum, pancreatitis, anorexia – polydipsia • Renal – hypercalciuria, polyuria (Na and K loss), nycturia, albuminuria – nephrolithiasis, nephrocalcinosis, azotaemia, renal insufficiency • Neural – emotional instability, delirium, psychosis – neuromuscular disorders, muscle weakness • Circulation – hypertension, short QT, impulse formation and conduction problems Hyperparathyroidism (PTH↑) • Primary hyperparathyroidism – Parathyroid adenoma – PTH producing tumor (MEN) – Lab param.: se Ca ↑, se P ↓ • Secondary hyperparathyroidism – Reactive PTH overproduction (cause: hypocalcaemia) – eg. kidney insufficiency – Lab param.: se Ca ↑, se P ↑ • Tertiary hyperparathyroidism – After a long period of secondary hyperparathyrosidism in patients with kidney insufficiency – autonomous PTH hypersecretion, no response to drugs – Therapy: surgical removal (3 + half gland) – Lab param.: se Ca ↑, se P ↑ Primary hyperparathyroidism Increased resorption of bone surfaces Increased number of osteoclasts, osteocytic osteolysis Consequences of hypercalcemia • Gastrointestinal – obstipatio, nausea, vomitting; ileus, abdominal pain – ulcus pepticum, pancreatitis, anorexia – polydipsia • Renal – hypercalciuria, polyuria (Na and K loss), nycturia, albuminuria – nephrolithiasis, nephrocalcinosis, azotaemia, renal insufficiency • Neural – emotional instability, delirium, psychosis – neuromuscular disorders, muscle weakness • Circulation – hypertension, short QT, impulse formation and conduction problems Dental signs and symptoms • • • • • Increased calcium levels in the saliva Increased calculus formation Widening of the periodontal space Absence of lamina dura Cystic lesions in the jawbone; filled with granulomatous tissue - epulis Familial hypocalciuric hypercalcemia (FHH) • Genetic, autosomal dominant • Mimics primary hyperparathyroidism • PTH slightly high, however inappropriate for level of calcium • Mutation in parathyroid calcium sensor – Higher setpoint • Low urinary calcium/creatinine <0.01 • No end organ damage • No treatment required Malignancy associated hypercalcemia • Most common cause of hypercalcaemia in hospitalized patients • Humoral hypercalcaemia (paraneoplastic) – Tumor cells may secrete: • PTH, PTHrP • 1,25(OH)D3 • RANKL – Epithelial cc (lung, cervix); bladder cancer; ovarial cancer; lymphomas; multiple myeloma • Local osteolytic hypercalcaemia – Direct osteolytic effetc of tumor metastases in the bones • PTHrP (PTH-related Protein) – structure similar to PTH, same receptor, autocrine/paracrine effects – not synthesized in parathyroids, no role in endocrine regulation of Ca-P – Physiological importance: fetal and neonatal bone development – Produced in uterus and placenta of pregnants, and in lactating breast – Pathology: secreted by bronchial-, breast-, kidney-, bladder-, esophageal cc. cells Granulomatous disease • Sarcoidosis, Tuberculosis, Leprosy • Activation of 1 alpha hydroxylase (macrophage) – conversion 25-OH Vitamin D increased level of 1,25(OH) Vitamin D • PTH low • Treatment: glucocorticoids Secondary hyperparathyroidism Chronic hypocalcemia secondary hyperparathyroidism • Chronic renal failure (most important) • Dietary deficiency of vitamin D or calcium • Decreased intestinal absorption of vitamin D • Drugs that cause rickets or osteomalacia (phenytoin, phenobarbital etc.) • Excessive intake of inorganic phosphate compound • Pseudohypoparathyroidism • Severe hypomagnesemia Milk-alkali syndrome (Burnett’s syndrome) • Hypercalcemia from excess ingestion alkali and calcium – Excessive Milk or calcium supplements – Excessive soluble alkali (absorbable antacid) – Sodium bicarbonate, calcium carbonate – Potentiated by Vitamin D supplementation • Chronic milk-alkali leads to renal insufficiency – Soft tissue calcification of kidneys – Nephrocalcinosis Milk-alkali syndrome (Burnett’s syndrome) Usually peptic ulcer, or similar complaints P homeostasis Etiologies of Hyperphosphatemia • Increased GI intake – Fleet’s phospho-soda • Decreased urinary excretion – Renal failure – Low PTH (hypoparatyrodism) • after thyroidectomy, after I131 treatment, autoimmune • Cell lysis – Rabdomyolysis – Tumor lysis syndrome Etiologies of Hypophosphatemia • Decreased GI Absorption – Decreased dietary intake (rare in isolation) – Diarrhea / Malabsorption – Phosphate binders (calcium acetate, Al & Mg containing antacids) • Decreased bone resorption / Increased bone mineralization – Vitamin D deficiency / low calcitriol – Hungry bones syndrome – Osteoblastic metastases • Increased urinary excretion – Elevated PTH (as in primary hyperparathyroidism) – Vitamin D deficiency / low calcitriol – Fanconi syndrome • Internal redistribution FGF-23 and its role in the phosphate homeostasis • Fibroblast growth factor-23 • Produced mainly by bone and connective tissue • Effects – In the kidney • inhibits tubular P reuptake – phosphaturia • inhibits 1α-hydroxilase activity – Induces 24-hydroxilase activity (calcitriol ↓) • FGF23 mRNA expression is stimulated by: – calcitriol – hyperphosphataemia (indirect effect) Regulation of FGF-23 FGF23 induced disorders of phosphate metabolism • Common: FGF23↑ • Symptoms: – hypophosphataemia, low calcitriol level, BMD↓ (bone density) • Genetic diseases: – X-linked hypophosphataemia (XLH) • Mutation of PHEX gene, inactive PHEX protein /1:20000/) – (PHEX: „phosphate-regulating gene with homologies to endopeptidases on the X-chromosome”) • Function of PHEX: inactivates FGF23 (indirect effect) – Autosom. dom. hypophosphataemic ricketts (ADHR) • rare; mutant FGF23, resists proteolysis: high circulating FGF23 levels • Tumor induced osteomalacia (TIO) – Mainly benign mesenchymal tumors produce FGF23 Metabolic bone diseases Normal Matrix Minerals Osteoporosis Osteomalacia Combined Model of risk factors Osteoporosis A systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture. • • • • • • • Chronic pain Height loss Kyphosis Decreased self-esteem Restrictive lung dx Constipation, abdominal pain Depression Trabecular structure in osteoporosis Importance of osteoporosis Risk factors for osteoporotic fractures: • Hypogonadism in men • Personal history of fracture as an adult • Alcoholism • History of fracture in a first degree relative • Current cigarette smoking • Caucasian • Low calcium intake (lifelong) • Female • Inadequate physical activity • Low body weight (<55 kg) • Dementia Estrogen deficiency • Recurrent Falls Early menopause (<age 45) • Poor health/frailty Bilateral oopherectomy Prolonged amenorrhea (>1 yr) Classification of ostoporosis Primary • Postmenopausal – Decreased estrogen results in increased osteoclastic activity without increased osteoblastic activity – Bone loss – 2-3% per year of total bone mass – Most common fx: vertebral, distal forearm • Age related – 3rd decade of life starts slow decline in bone mass at rate of 0.5-1% per year – Most common types of fx: hip and radius – F>M Secondary Risk factors of osteoporosis Pathogenesis of Type I osteoporosis Pathogenesis of Type II osteoporosis Osteomalatia Vitamin D – the dentists point of view • D – vitamin overdose » Hypoplastic enamel (if during tooth development ) • D – vitamin deficinecy - Dentin: dentinmatrix problems (irregular dentin-predentin interface) - Enamel: thin, decreased mineralization, irregular surface;